Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-20T06:42:15.087Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of tianeptine in the treatment of major depression and depressed bipolar disorders. Illustration of the interest of surveillance of a European multicentre double-blind study in progress: tianeptine versus placebo and imipramine

Published online by Cambridge University Press:  16 April 2020

L Staner  and
J Mendlewicz
L Staner
Affiliation:
Hôpital Universitaire Erasme, Route de Lennik 808, B-1070, Brussels, Belgium
J Mendlewicz
Affiliation:
Hôpital Universitaire Erasme, Route de Lennik 808, B-1070, Brussels, Belgium
Get access

Summary

In the course of the international development of tianeptine (T), depressed patients were recruited by 15 centres from Belgium, Italy, Portugal, Spain and Switzerland in a double-blind parallel group study versus placebo (P) and imipramine (I). Efficacy and safety of tianeptine are evaluated in the treatment of major depressions (single episode or recurrent) and depressed bipolar disorders. The initial severity of the depression is controlled by a MADRS score equal to or greater than 25. Rapid placebo responded are excluded during a placebo pre-inclusion period (duration: 1 week). After an increasing daily dose period (3 days), depressed patients are treated, until the 14th day (D14), at a constant daily dose (T: 37.5 mg; I: 150 mg; P: 3 capsules). After D14 and until the end of the 6th week, a flexible dosage can be used in accordance with the therapeutic efficacy and/or the potential adverse events (T: 25–50 mg; I: 100–200 mg; P: 2–4 capsules). The antidepressant efficacy is regularly evaluated by rating scales (MADRS, HSCL). Anxiety linked to depression is evaluated by the Hamilton Anxiety Rating Scale. The safety is controlled by clinical examination, laboratory parameters and a check-list of side-effects. Preliminary results are presented and discussed showing the interest of surveillance of trials in progress.

Keywords

depressiontianeptineimipramineplacebodouble-blind trial
Type
Research Article
Information
European Psychiatry , Volume 8 , Issue S2: Neuroendocrinological aspects of depression 28 June 1992, Nice, France , 1993 , pp. 111s - 115s
Copyright
Copyright © Elsevier, Paris 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

Based on a presentation given at the XVIIIth CINP Congress, in Nice, June 28-July 2, 1992.

References

American Psychiatric Association (APA) (1987) Diagnostic and Statistical Manual of Mental Disorders. DSM III-R 3rd edn, revised, WashingtonGoogle Scholar
Bobon, DP (1982) Le système AMDP (Mordaga, P ed). BruxellesGoogle Scholar
Davis, J (1985) Antidepressant drugsIn: Comprehensive Textbook of Psychiatry/IV (Kaplan, HISadock, BJ eds). Williams and Wilkins, Baltimore, London, Los Angeles, Sidney, 1513–1537Google Scholar
Derogatis, LRLipman, RSRickels, KUhlenhuth, EHCovi, L (1974) The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory Behav Sci 19, 1–15CrossRefGoogle ScholarPubMed
Guelfi, JD (1992) Efficacy of tianeptine in comparative trials versus reference antidepressants: an overview Br J Psychiatry 160 (suppl 15), 72–75CrossRefGoogle Scholar
Guelfi, JDPichot, PDreyfus, JF (1989) Efficacy of tianeptine in anxious-depressed patients. Results of a controlled multicenter trial versus amitriptyline Neuropsychobiol 22, 41–18CrossRefGoogle ScholarPubMed
Hamilton, M (1959) The assessment of anxiety states by rating Br J Psychol 32, 50–55CrossRefGoogle ScholarPubMed
Labrid, CMoleyre, JPoignant, JCMalen, CMocaër, EKamoun, A (1988) Structure-activity relationships of tricyclic antidepressants, with special reference to tianeptine Clin Neuropharmacol 11 (suppl 2), S21–S3IGoogle ScholarPubMed
Labrid, CMocaër, EKamoun, A (1992) Neurochemical and pharmacological properties of tianeptine, a novel antidepressant Br J Psychiatry 60 (suppl 15), 56–60CrossRefGoogle Scholar
Lôo, HDavy, JPZarifian, E (1987) Les antidépresseurs Encycl Mèd Chir (Paris-France) Psychiatrie, 37860 B70, 1–27Google Scholar
Lôo, HGanry, HDufour, HGuelfi, JDMalka, ROlié, JPScharbach, HTignol, JMarey, CKamoun, A (1992) Long term treatment with tianeptine in 380 depressed patients Br J Psychiatry 160 (suppl 15), 61–65CrossRefGoogle Scholar
Lôo, HMalka, RDefrance, RBarrucand, DBenard, JYNiox-Rivière, HRaab, ASarda, AVachonfrance, GKamoun, A (1988) Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients Neuropsychobiol 19, 79–85CrossRefGoogle ScholarPubMed
Mendlewicz, J (1989) The social burden of depressive disorders Neuropsychobiology 22, 178–180CrossRefGoogle ScholarPubMed
Mocaër, ERettori, MCKamoun, A (1988) Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase Clin Neuropharmacol 11 (Suppl 2), S32–S42Google ScholarPubMed
Montgomery, SAÅsberg, M (1979) A new depression scale designed to be sensitive to change Br J Psychiatry 134, 382–389CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.